Article Sidebar

Submitted
9 July 2024
Published
30 December 2024
Download
PDF
Statistic
Read Counter : 129 Download : 109

Main Article Content

Abstract

BPJS Kesehatan aims to improve the health of participants suffering from Type 2 DM through the Chronic Disease Management Program “Prolanis” (Program Pengelolaan Penyakit Kronis) strategy implemented at Primary Health Care (PHC). Program success is measured by the outcomes of controlled Fasting Blood Sugar status and the cost-effectiveness of Prolanis. This research was conducted to determine the cost-effectiveness of Prolanis in treating Type 2 DM. Analytical cross-sectional research using secondary data from BPJS Kesehatan in the Sibolga Branch Office work area in 2020-2022 on Type 2 DM participants who took Prolanis and Non-Prolanis. The analysis used univariate, bivariate, multiple logistic regression, and ICER cost analysis. Characteristics of Prolanis participants, age, number of visits, and Body Mass Index showed a significant relationship with the achievement of controlled fasting blood sugar. The average fasting blood sugar of Prolanis and Non-Prolanis participants in 2021-2022 did not significantly differ. Still, the proportion of controlled fasting blood sugar of Prolanis participants was greater than that of Non-Prolanis participants. The total cost of Prolanis in a row for 2020-2022 is IDR 1,437,411,273, IDR 2,706,895,281, and IDR 2,751,510,452. The total cost of Non Prolanis for 2020-2022 is IDR 5,861,773,361; IDR 7,807,455,547,-; IDR 10,291,812,544,-. The ICER for each controlled fasting blood sugar proportion varies from 2020-2022 IDR 462,489; IDR 201,473;  IDR 362,856. Prolanis expenditure at the Sibolga Branch Office is higher, but the clinical effectiveness of the proportion of controlled fasting blood sugar participants is better than that of non-Prolanis participants

Keywords

Disease Management Program Prolanis Fasting Blood Sugar Cost-effectiveness Incremental Cost Effectiveness Ratio

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
sitompul, E. M. S., & As Shidieq, F. H. . (2024). Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga. Jurnal Jaminan Kesehatan Nasional, 4(2), 251–268. https://doi.org/10.53756/jjkn.v4i2.251
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Alkaff, F. F., Illavi, F., Salamah, S., Setiyawati, W., Ramadhani, R., Purwantini, E., & Tahapary, D. L. (2021). The Impact of the Indonesian Chronic Disease Management Program (PROLANIS) on Metabolic Control and Renal Function of Type 2 Diabetes Mellitus Patients in Primary Care Setting. Journal of Primary Care and Community Health, 12. https://doi.org/10.1177/2150132720984409
  2. Arnold, R. J. . (2021). Pharmacoeconomics From Theory to Practice. In Analytical Biochemistry: Vol. Second Edi (Second Edi, Issue 1). CRS Press.
  3. Aryani, A. D., Kurdi, F. N., & Soebyakto, B. B. (2016). Cost Effectiveness Analysis ( CEA ) Program Pengelolaan Penyakit Kronis ( PROLANIS ) Diabetes Melitus Tipe 2 Peserta JKN di Kota Serang Banten Sebanyak 10 juta penduduk Indonesia BPJS Kesehatan melaksanakan Disease Management Program ( DMP ) atau dikenal. Kedokteran Dan Kesehatan, 3(3), 146–154.
  4. Carbone, S., Del Buono, M. G., Ozemek, C., & Lavie, C. J. (2019). Obesity, risk of diabetes and role of physical activity, exercise training, and cardiorespiratory fitness. Progress in Cardiovascular Diseases, 62(4), 327–333. https://doi.org/10.1016/j.pcad.2019.08.004
  5. DJSN. (2022). Dewan Jaminan Sosial Nasional Sistem Monitoring Terpadu. http://180.250.242.162/
  6. Fazeli, P. K., Lee, H., & Steinhauser, M. L. (2020). Aging Is a Powerful Risk Factor for Type 2 Diabetes Mellitus Independent of Body Mass Index. Gerontology, 66(2), 209–210. https://doi.org/10.1159/000501745
  7. Fukuda, H., & Mizobe, M. (2017). Impact of nonadherence on complication risks and healthcare costs in patients newly diagnosed with diabetes. Diabetes Research and Clinical Practice, 123, 55–62. https://doi.org/10.1016/j.diabres.2016.11.007
  8. Issaka, A., Cameron, A. J., Paradies, Y., Bosu, W. K., Houehanou, Y. C. N., Kiwallo, J. B., Wesseh, C. S., Houinato, D. S., Nazoum, D. J. P., & Stevenson, C. (2022). Effect of age and sex on the associations between potentially modifiable risk factors and both type 2 diabetes and impaired fasting glycemia among West African adults. BMC Public Health, 22(1), 1–11. https://doi.org/10.1186/s12889-022-13588-w
  9. Kesehatan BPJS. (2019). PerDir BPJS Kesehatan. In Peraturan Direktur Badan Penyelenggara Jaminan Sosial Kesehatan Nomor 3.
  10. Liang, D., Zhu, W., Huang, J., & Dong, Y. (2023). A health economic analysis of an integrated diabetes care program in China: based on real-world evidence. Frontiers in Public Health, 11(December), 1–10. https://doi.org/10.3389/fpubh.2023.1211671
  11. Rahmadhanie, A. K. (2019). Program Pengelolaan Penyakit Kronis (Prolanis) oleh Dokter Keluarga sebagai Penanganan Hipertensi dan Diabetes Mellitus Tipe 2. Universitas Sebelas Maret Surakarta, 2(1), 3–4.
  12. Riedl, R., Robausch, M., & Berghold, A. (2016). The evaluation of the effectiveness of Australian disease management program in patients with type 2 diabetes mellitus - A population-based retrospective cohort study. PLoS ONE, 11(8), 1–13. https://doi.org/10.1371/journal.pone.0161429
  13. Salamah, S., Khafiyya, A. N., Ramadhani, R., Arfiana, M. R., Syamsuri, I., Faizah, N. N., Nugraha, D., Arifin, B., & Alkaff, F. F. (2023). Outcomes of the Indonesian Chronic Disease Management Program (PROLANIS) in Patients with Hypertension During the COVID-19 Pandemic in Rural Areas: A Preliminary Evaluation Study. Medical Science Monitor, 29, 1–9. https://doi.org/10.12659/MSM.939797
  14. Sari, C. W. M., Witdiawati, W., Purnama, D., & Kurniawan, T. (2022). Evaluation of Diabetes Patients About Chronic Disease Management Program in Bandung. Malaysian Journal of Medicine and Health Sciences, 18(11), 70–75.
  15. Sekhar, R. V. (2022). ‘Analogy-Based Comprehensive Diabetes Education’ (ABCDE) Improves Glycemic Control of Diabetic Patients in an Underserved Population: Results of a Retrospective Chart Analysis. Healthcare (Switzerland), 10(3). https://doi.org/10.3390/healthcare10030409
  16. Simcoe, T., Catillon, M., & Gertler, P. (2019). Who benefits most in disease management programs: Improving target efficiency. Health Economics (United Kingdom), 28(2), 189–203. https://doi.org/10.1002/hec.3836
  17. Talavera, G. A., Castañeda, S. F., Mendoza, P. M., Lopez-Gurrola, M., Roesch, S., Pichardo, M. S., Garcia, M. L., Muñoz, F., & Gallo, L. C. (2021). Latinos understanding the need for adherence in diabetes (LUNA-D): A randomized controlled trial of an integrated team-based care intervention among Latinos with diabetes. Translational Behavioral Medicine, 11(9), 1665–1675. https://doi.org/10.1093/tbm/ibab052
  18. WHO. (2022). Implementation roadmap for accelerating the prevention and control of noncommunicable diseases in South-East Asia 2022–2030 (Issue 8.5.2017). World Health Organization Regional Officer for South-East Asia.